Concept Foundation is happy to announce that Incepta Pharmaceuticals (Bangladesh) has been awarded WHO Prequalification of their intramuscular (IM) depot medroxyprogesterone acetate (DMPA) 150 mg/ml product. The Incepta product adds a second generic DMPA product to the WHO PQ list, alongside Mylan’s product, thereby increasing the volume of quality assured 3 monthly injectable contraception available worldwide and easing the current DMPA shortage impacting the Reproductive Health Supplies community. This result also supports the ongoing Family Planning 2020 movement’s goal of expanding access to family planning services to an additional 120 million women and girls in the 69 Family Planning 2020 countries.
Concept Foundation has been working in partnership with Incepta towards reaching this goal since 2013 with funding from the Bill and Melinda Gates Foundation (BMGF) under its programme “Addressing the barriers to making quality assured 3 monthly injectable contraception more widely available”. This programme allowed Concept Foundation to work closely with selected manufacturers of generic IM DMPA to reach international quality assurance standards, achieve WHO PQ and increase access to injectable contraception in lower and middle income countries.